1/2 Allogeneic Human Mesenchymal Stem Cell (MSC) Injection in Patients with Hypoplastic Left Heart Syndrome: A Phase IIb Clinical Trial
1/2 Allogeneic Human Mesenchymal Stem Cell (MSC) Injection in Patients with Hypoplastic Left Heart Syndrome: A Phase IIb Clinical Trial
批准号:
10295008
负责人:
Joshua M Hare
金额:
$65.79万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-09-15 至 2021-08-31
中文摘要
同种异体人间充质干细胞(MSC)注射在发育不良患者中的应用
英文摘要
This application for the "Allogeneic Human Mesenchymal Stem Cell (MSC) Injection in Patients with Hypoplastic
Left Heart Syndrome: A Phase IIb Clinical Trial (ELPIS)" Clinical Coordinating Center (CCC) is collaborative with
the ELPIS Data Coordinating Center (DCC) application. The CCC will have ultimate responsibility for managing
the ELPIS clinical consortium of six clinical sites, meeting, planning enrollment milestones, distributing CCC
resources, and overseeing all aspects of clinical design of the studies. Hypoplastic Left Heart Syndrome (HLHS)
is one of the most complex forms of congenital heart disease (CHD), with a reported incidence of 0.2 per 1000
live births or 3% of children born with CHD. Once a universally fatal diagnosis, dramatic improvements in three
staged palliative operations now allow the single right ventricle (RV) to functionally support the circulation.
Despite these strides in medical care, the mortality rate of these infants remains as high as 25 to 35 percent
during the first year of life and continues with a high mortality rate for the rest of their life. Those surviving
childhood are likely to progress towards cardiac transplantation, usually due to failure of the systemic RV. To
address this RV dysfunction, our stem cell trial is based on a decade of basic research and the ELPIS Phase I
study using allogeneic MSCs in HLHS patients at the Stage II operation. Our completed enrolled ELPIS Phase
I study supports both the feasibility for this investigative strategy and the safety profile of the allogeneic MSCs.
Secondary endpoints demonstrated that the initial MSC treated patients showed by cardiac MRI (CMR) no
difference in RV ejection fraction, or end diastolic volumes, however a significant decrease in RV mass was
present, a surrogate for decreased hypertrophy. Our hypothesis for this trial is that intramyocardial delivery of
allogeneic MSCs will improve the performance of the single systemic RV in HLHS patients at the Stage II
operation. A total of 36 HLHS patients who are undergoing the Stage II operation will be single blinded and
randomized to either receive MSC treatment or standard of care. Patients will be followed for one year. The
primary outcome measurement will be decrease in RV mass as determined by CMR studies at baseline, 6 and
12 months following MSC injection. Secondary outcomes will include improvements in clinical and physiologic
endpoints, improvements seen by other global RV cardiac function parameters measured by serial CMR studies,
exosome biomarker analysis and safety endpoints. This single blinded randomized clinical trial is designed to
address the following specific aims: (1) to analyze MSC delivery for RV function improvement at the Stage II
operation; (2) to determine dynamic changes of the amount and composition of plasma biomarkers derived from
the transplanted MSCs; and (3) to analyze safety of MSC treatment. Although not planned as a survival study,
we anticipate that the proposed study will provide valuable data on the safety and benefit of MSC treatment in
HLHS patients. The sufficiently definitive information will inform the decision on whether to proceed with a Phase
III clinical trial of therapeutic MSC delivery to reduce mortality in HLHS patients and to direct its study design.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Full-scale GMP Production for a Pre-Clinical Systemic Delivered Mesenchymal Stem Cells Derived Extracellular Vesicles For Cardiovascular Disease
-
批准号:10721103
-
项目类别:
-
资助金额:$28.87万
-
财政年份:2023
-
负责人:Joshua M Hare
-
依托单位:
1/2 Allogeneic Human Mesenchymal Stem Cell (MSC) Injection in Patients with Hypoplastic Left Heart Syndrome: A Phase IIb Clinical Trial
-
批准号:10274833
-
项目类别:
-
资助金额:$117.83万
-
财政年份:2020
-
负责人:Joshua M Hare
-
依托单位:
Production Assistance for Cellular Therapies (PACT)- Cell Processing Facilities Cell manufacturing and process development services for PCT0031-02: GMP Production of iPSC Line and Scale-up of Cardiac
-
批准号:10090766
-
项目类别:
-
资助金额:$101.72万
-
财政年份:2019
-
负责人:Joshua M Hare
-
依托单位:
A Phase 2b Clinical Trial to Study the Efficacy of Longeveron Mesenchymal Stem Cells (LMSCs) to Treat Aging Frailty
-
批准号:9922198
-
项目类别:
-
资助金额:$197.43万
-
财政年份:2018
-
负责人:Joshua M Hare
-
依托单位:
A Randomized, Blinded, Placebo-Controlled Clinical Trial to Evaluate Longeveron Mesenchymal Stem Cell (LMSC) Therapy for Treating The Metabolic Syndrome
-
批准号:9925908
-
项目类别:
-
资助金额:$46.55万
-
财政年份:2017
-
负责人:Joshua M Hare
-
依托单位:
A Randomized, Blinded, Placebo-Controlled Clinical Trial to Evaluate Longeveron Mesenchymal Stem Cell (LMSC) Therapy for Treating The Metabolic Syndrome
-
批准号:9348026
-
项目类别:
-
资助金额:$15.0万
-
财政年份:2017
-
负责人:Joshua M Hare
-
依托单位:
Nitric Oxide and sex differences in cardiac repair
-
批准号:9331951
-
项目类别:
-
资助金额:$40.61万
-
财政年份:2017
-
负责人:Joshua M Hare
-
依托单位:
Pathways to Cardiovascular Therapeutics
-
批准号:8986055
-
项目类别:
-
资助金额:$3.0万
-
财政年份:2015
-
负责人:Joshua M Hare
-
依托单位:
Cell Based Therapy for Non-Ischemic Dilated Cardiomyopathy
-
批准号:8288406
-
项目类别:
-
资助金额:$71.55万
-
财政年份:2012
-
负责人:Joshua M Hare
-
依托单位:
Cell Based Therapy for Non-Ischemic Dilated Cardiomyopathy
-
批准号:8448599
-
项目类别:
-
资助金额:$65.07万
-
财政年份:2012
-
负责人:Joshua M Hare
-
依托单位:
Cell Based Therapy for Non-Ischemic Dilated Cardiomyopathy
-
批准号:8628873
-
项目类别:
-
资助金额:$66.46万
-
财政年份:2012
-
负责人:Joshua M Hare
-
依托单位:
Cardioprotective Effect of Growth Hormone Releasing Hormone
-
批准号:8065336
-
项目类别:
-
资助金额:$64.43万
-
财政年份:2011
-
负责人:Joshua M Hare
-
依托单位:
Cardioprotective Effect of Growth Hormone Releasing Hormone
-
批准号:8208055
-
项目类别:
-
资助金额:$62.55万
-
财政年份:2011
-
负责人:Joshua M Hare
-
依托单位:
Stem Cells for Dilated Cardiomyopathy
-
批准号:8502552
-
项目类别:
-
资助金额:$62.02万
-
财政年份:2011
-
负责人:Joshua M Hare
-
依托单位:
Cardioprotective Effect of Growth Hormone Releasing Hormone
-
批准号:8411600
-
项目类别:
-
资助金额:$64.93万
-
财政年份:2011
-
负责人:Joshua M Hare
-
依托单位:
Stem Cells for Dilated Cardiomyopathy
-
批准号:8300026
-
项目类别:
-
资助金额:$65.13万
-
财政年份:2011
-
负责人:Joshua M Hare
-
依托单位:
Stem Cells for Dilated Cardiomyopathy
-
批准号:8880266
-
项目类别:
-
资助金额:$60.41万
-
财政年份:2011
-
负责人:Joshua M Hare
-
依托单位:
Stem Cells for Dilated Cardiomyopathy
-
批准号:8205725
-
项目类别:
-
资助金额:$63.95万
-
财政年份:2011
-
负责人:Joshua M Hare
-
依托单位:
Cardioprotective Effect of Growth Hormone Releasing Hormone
-
批准号:8589378
-
项目类别:
-
资助金额:$64.84万
-
财政年份:2011
-
负责人:Joshua M Hare
-
依托单位:
Stem Cells for Dilated Cardiomyopathy
-
批准号:8680353
-
项目类别:
-
资助金额:$63.89万
-
财政年份:2011
-
负责人:Joshua M Hare
-
依托单位:
国内基金
海外基金
靶向Human ZAG蛋白的降糖小分子化合物筛选以及疗效观察
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:胡文静
-
依托单位:
HBV S-Human ESPL1融合基因在慢性乙型肝炎发病进程中的分子机制研究
-
批准号:81960115
-
项目类别:地区科学基金项目
-
资助金额:34.0万元
-
批准年份:2019
-
负责人:江建宁
-
依托单位:
基于自适应表面肌电模型的下肢康复机器人“Human-in-Loop”控制研究
-
批准号:61005070
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2010
-
负责人:李庆玲
-
依托单位: